Ultragenyx Pharmaceutical | RARE - Assets


Ultragenyx Pharmaceutical reported $1.3B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
Immunic USD 189.74M 165.69M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Kyowa Hakko Kirin JPY 1.07T 40.7B Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Moderna USD 11.49B 850M Mar/2026
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026
Xoma USD 263.15M 39.7M Sep/2025